Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LRK-4189 alone and with mFOLFOX6 or FOLFIRI in advanced solid tumors
2026-525629-20-00Phase 2Authorised
- Sponsor
- Larkspur Biosciences
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of LRK-4189 in Nonhematologic neoplasms (3 arms), sponsored by Larkspur Biosciences. Primary endpoints: Safety, tolerability, PK, PD, and target lesion shrinkage, Antitumor efficacy by RECIST 1.1 and 1 more. Planned start Jul 2026; status: authorised.
02
Drugs
LRK-4189
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2026-525629-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525629-20-00.